Literature DB >> 15890427

Prevalence and control of dyslipidemia among persons with diabetes in the United States.

Milagros J Jacobs1, Thomas Kleisli, Jose R Pio, Shaista Malik, Gilbert J L'Italien, Roland S Chen, Nathan D Wong.   

Abstract

OBJECTIVE: We assessed the prevalence, treatment, and control of dyslipidemia among United States (U.S.) adults with diabetes.
METHODS: Among 498 adults (projected to 13.4 million) aged >or=18 years with diabetes representative of the U.S. population and surveyed within the cross-sectional National Health and Nutrition Examination Survey 1999-2000, control of lipids was classified according to American Diabetes Association criteria. The extent of low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and triglyceride (TG) control was examined by gender and ethnicity, in comparison to those without diabetes, and according to lipid-lowering treatment. Analyses were weighted to the U.S. population.
RESULTS: Less than one-third of men and only one-fifth of women with diabetes are in control for LDL-C, defined as <2.6 mmol/l (<100mg/dl); over 70% are not at goal. Over half of men and over two-thirds of women have low levels of HDL-C (<or=1.0 mmol/l [<40 mg/dl] in men or <or=1.3 mmol/l [<or=50mg/dl] in women) and over half have elevated levels of triglycerides (>or=1.7 mmol/l [150 mg/dl]). Low HDL-C was more common in Caucasians (70.1%) than in Hispanics (58.8%) or African-Americans (41.5%) (p<0.001). 28.2% of subjects with diabetes were on lipid-lowering treatment. Control of LDL-C did not differ by treatment status and only 3% of subjects were controlled to target levels for all lipids.
CONCLUSION: Many persons with diabetes remain uncontrolled for dyslipidemia. Intensified efforts at screening and treatment according to current guidelines are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890427     DOI: 10.1016/j.diabres.2005.03.032

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  31 in total

Review 1.  Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found.

Authors:  Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2010-09       Impact factor: 5.113

Review 2.  Niacin: another look at an underutilized lipid-lowering medication.

Authors:  Julia C Creider; Robert A Hegele; Tisha R Joy
Journal:  Nat Rev Endocrinol       Date:  2012-02-21       Impact factor: 43.330

Review 3.  Cardiovascular disease in type 1 diabetes.

Authors:  Harish Sharma; Mauro Lencioni; Parth Narendran
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-02-13

4.  Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1.

Authors:  Lina Basel-Vanagaite; Noam Zevit; Adi Har Zahav; Liang Guo; Saj Parathath; Metsada Pasmanik-Chor; Adam D McIntyre; Jian Wang; Adi Albin-Kaplanski; Corina Hartman; Daphna Marom; Avraham Zeharia; Abir Badir; Oded Shoerman; Amos J Simon; Gideon Rechavi; Mordechai Shohat; Robert A Hegele; Edward A Fisher; Raanan Shamir
Journal:  Am J Hum Genet       Date:  2012-01-05       Impact factor: 11.025

5.  Initiation of treatment for incident diabetes: evidence from the electronic health records in an ambulatory care setting.

Authors:  Sukyung Chung; Beinan Zhao; Diane Lauderdale; Randolph Linde; Randall Stafford; Latha Palaniappan
Journal:  Prim Care Diabetes       Date:  2014-05-05       Impact factor: 2.459

Review 6.  Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management.

Authors:  Joe M Chehade; Margaret Gladysz; Arshag D Mooradian
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

Review 7.  Diabetes: managing dyslipidaemia.

Authors:  Jigisha Patel
Journal:  BMJ Clin Evid       Date:  2008-06-09

8.  Cost sharing and the initiation of drug therapy for the chronically ill.

Authors:  Matthew D Solomon; Dana P Goldman; Geoffrey F Joyce; José J Escarce
Journal:  Arch Intern Med       Date:  2009-04-27

9.  Distinct component profiles and high risk among African Americans with metabolic syndrome: the Jackson Heart Study.

Authors:  Herman Taylor; Jiankang Liu; Gregory Wilson; Sherita H Golden; Errol Crook; Claude D Brunson; Micheal Steffes; William D Johnson; Jung Hye Sung
Journal:  Diabetes Care       Date:  2008-03-10       Impact factor: 19.112

10.  High dietary cholesterol masks type 2 diabetes-induced osteopenia and changes in bone microstructure in rats.

Authors:  Sarawut Lapmanee; Narattaphol Charoenphandhu; Ratchaneevan Aeimlapa; Panan Suntornsaratoon; Kannikar Wongdee; Wacharaporn Tiyasatkulkovit; Kanchana Kengkoom; Khuanjit Chaimongkolnukul; Dutmanee Seriwatanachai; Nateetip Krishnamra
Journal:  Lipids       Date:  2014-09-09       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.